BR112017009595A2 - morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4) - Google Patents

morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)

Info

Publication number
BR112017009595A2
BR112017009595A2 BR112017009595A BR112017009595A BR112017009595A2 BR 112017009595 A2 BR112017009595 A2 BR 112017009595A2 BR 112017009595 A BR112017009595 A BR 112017009595A BR 112017009595 A BR112017009595 A BR 112017009595A BR 112017009595 A2 BR112017009595 A2 BR 112017009595A2
Authority
BR
Brazil
Prior art keywords
sstr4
oxazepane
somatostatin
agonists
morpholine
Prior art date
Application number
BR112017009595A
Other languages
English (en)
Inventor
Lingard Iain
Rudolf Klaus
Ferrara Marco
Giovannini Riccardo
Mazzaferro Rocco
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112017009595A2 publication Critical patent/BR112017009595A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

a presente invenção refere-se aos derivados de morfolina e 1,4-oxazepano amida de fórmula geral (i), os quais são agonistas do subtipo de receptor de somatostatina 4 (sstr4), úteis para prevenir ou tratar os distúrbios médicos relacionadas com o sstr4. além disso, a invenção refere-se aos processos para a preparação de composições farmacêuticas, assim como aos processos para a fabricação dos compostos de acordo com a invenção.
BR112017009595A 2014-11-14 2015-11-12 morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4) BR112017009595A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14193185 2014-11-14
PCT/EP2015/076440 WO2016075240A1 (en) 2014-11-14 2015-11-12 Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists

Publications (1)

Publication Number Publication Date
BR112017009595A2 true BR112017009595A2 (pt) 2017-12-19

Family

ID=51904765

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009595A BR112017009595A2 (pt) 2014-11-14 2015-11-12 morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)

Country Status (14)

Country Link
US (2) US10071974B2 (pt)
EP (1) EP3218372B1 (pt)
JP (1) JP6641367B2 (pt)
KR (1) KR20170082632A (pt)
CN (1) CN107108592B (pt)
AU (1) AU2015345070A1 (pt)
BR (1) BR112017009595A2 (pt)
CA (1) CA2965566A1 (pt)
CL (1) CL2017001181A1 (pt)
EA (1) EA032104B1 (pt)
IL (1) IL251465A0 (pt)
MX (1) MX370366B (pt)
PH (1) PH12017500821A1 (pt)
WO (1) WO2016075240A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (pt) 2014-01-24 2018-02-24
EP3053452A1 (en) * 2015-01-16 2016-08-10 Interquim, S.A. Naturally derived colour stabilizer
US20180028541A1 (en) * 2016-07-29 2018-02-01 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis
US11912687B2 (en) 2017-05-12 2024-02-27 Board of Trustees of the Southern Illinois University 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
US11136312B2 (en) 2017-05-12 2021-10-05 Board of Trustees of the Southern Illinois University 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
UA126829C2 (uk) * 2018-03-01 2023-02-08 Такеда Фармасьютікал Компані Лімітед Піперидиніл-3-(арилокси)пропанаміди та пропаноати
WO2021233428A1 (zh) * 2020-05-21 2021-11-25 广州费米子科技有限责任公司 含氮饱和杂环化合物及其制备方法、药物组合物和应用
WO2022012534A1 (zh) * 2020-07-13 2022-01-20 广州费米子科技有限责任公司 含氮杂环化合物、药物组合物和应用
AR127055A1 (es) 2021-09-14 2023-12-13 Lilly Co Eli Sales agonistas de sstr4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377758T3 (es) 2004-11-12 2012-03-30 Bristol-Myers Squibb Company Compuestos tricíclicos basados en tiazolo[4,5-b]piridina imidazo-fusionada y composiciones farmacéuticas que los comprenden
WO2010059922A1 (en) 2008-11-21 2010-05-27 Ligand Pharmaceuticals Incorporated Pyrrolidine carboxamide compounds
US9382216B2 (en) 2011-03-10 2016-07-05 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor

Also Published As

Publication number Publication date
CA2965566A1 (en) 2016-05-19
CN107108592B (zh) 2021-01-29
EA201791058A1 (ru) 2017-11-30
JP6641367B2 (ja) 2020-02-05
US20180339971A1 (en) 2018-11-29
IL251465A0 (en) 2017-05-29
US10071974B2 (en) 2018-09-11
US10577336B2 (en) 2020-03-03
EP3218372B1 (en) 2020-05-20
MX370366B (es) 2019-12-11
EA032104B1 (ru) 2019-04-30
WO2016075240A1 (en) 2016-05-19
CN107108592A (zh) 2017-08-29
AU2015345070A1 (en) 2017-04-20
KR20170082632A (ko) 2017-07-14
PH12017500821A1 (en) 2017-10-02
EP3218372A1 (en) 2017-09-20
MX2017006231A (es) 2017-07-31
JP2017533930A (ja) 2017-11-16
CL2017001181A1 (es) 2018-02-02
US20170320838A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
BR112017009595A2 (pt) morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
BR112017002001A2 (pt) compostos e composição farmacêutica
PH12017500828A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
BR112017010893A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
PH12015502524A1 (en) New somatostatin receptor subtype 4 (sstr4) agonists
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
BR112016028273A8 (pt) derivados radiorrotulados de composto de 2-amino6-fluoro-n-[5-fluoro-piridin-3-il]-pirazol[1,5-a]pirimidin3-carboxamida úteis como inibidor de atr cinase, processo para preparação do referido composto, bem como diferentes formas sólidas do mesmo, uso destas, e composição farmacêutica
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
BR112017013258A2 (pt) Derivados de 5-[(piperazin-1-il)-3-oxo-propil]- imidazolidina-2,4-diona como inibidores de adamts para o tratamento de osteoartrite
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
BR112017023080A2 (pt) compostos benzimidazolona e benzotiazolona e uso dos mesmos como moduladores do receptor de ampa
BR112018007181A2 (pt) antagonistas de nr2b seletivos
BR112019004248A2 (pt) inibidores da dopamina-b-hidroxilase
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
CY1122172T1 (el) Τροποποιητες θειαζολης των a3 υποδοχεων αδενοσινης
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
EA201692216A1 (ru) Пирролидиновые модуляторы gpr40 для лечения заболеваний, таких как диабет
MX2019014438A (es) Derivados de acidos carboxilicos eficaces como inhibidores de la proteina quinasa.
BR112017005859A2 (pt) inibidores de aldosterona sintase
BR112017021114A8 (pt) Compostos heterocíclicos como inibidores de lsd1
IN2014MU00666A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements